Article (Scientific journals)
First-trimester cesarean scar pregnancy: a comparative analysis of treatment options from the international registry.
Kaelin Agten, Andrea; Jurkovic, Davor; Timor-Tritsch, Ilan et al.
2024In American Journal of Obstetrics and Gynecology, 230 (6), p. 669.e1 - 669.e19
Peer Reviewed verified by ORBi
 

Files


Full Text
PIIS0002937823007585.pdf
Publisher postprint (1.2 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
KCl; balloon treatment; complications; hemorrhage; hysterectomy; management; methotrexate; suction evacuation; surgical excision; Abortifacient Agents, Nonsteroidal; Methotrexate; Misoprostol; Humans; Female; Pregnancy; Adult; Ultrasonography, Prenatal; Vacuum Curettage; Misoprostol/therapeutic use; Uterine Artery Embolization; Cicatrix; Cesarean Section/adverse effects; Cesarean Section/statistics & numerical data; Pregnancy Trimester, First; Pregnancy, Ectopic/therapy; Pregnancy, Ectopic/surgery; Registries; Abortifacient Agents, Nonsteroidal/therapeutic use; Methotrexate/therapeutic use; Cesarean Section; Pregnancy, Ectopic; Obstetrics and Gynecology
Abstract :
[en] [en] BACKGROUND: A cesarean scar pregnancy is an iatrogenic consequence of a previous cesarean delivery. The gestational sac implants into a niche created by the incision of the previous cesarean delivery, and this carries a substantial risk for major maternal complications. The aim of this study was to report, analyze, and compare the effectiveness and safety of different treatments options for cesarean scar pregnancies managed in the first trimester through a registry. OBJECTIVE: This study aimed to evaluated the ultrasound findings, disease behavior, and management of first-trimester cesarean scar pregnancies. STUDY DESIGN: We created an international registry of cesarean scar pregnancy cases to study the ultrasound findings, disease behavior, and management of cesarean scar pregnancies. The Cesarean Scar Pregnancy Registry collects anonymized ultrasound and clinical data of individual patients with a cesarean scar pregnancy on a secure, digital information platform. Cases were uploaded by 31 participating centers across 19 countries. In this study, we only included live and failing cesarean scar pregnancies (with or without a positive fetal heart beat) that received active treatment (medical or surgical) before 12+6 weeks' gestation to evaluate the effectiveness and safety of the different management options. Patients managed expectantly were not included in this study and will be reported separately. Treatment was classified as successful if it led to a complete resolution of the pregnancy without the need for any additional medical interventions. RESULTS: Between August 29, 2018, and February 28, 2023, we recorded 460 patients with cesarean scar pregnancies (281 live, 179 failing cesarean scar pregnancy) who fulfilled the inclusion criteria and were registered. A total of 270 of 460 (58.7%) patients were managed surgically, 123 of 460 (26.7%) patients underwent medical management, 46 of 460 (10%) patients underwent balloon management, and 21 of 460 (4.6%) patients received other, less frequently used treatment options. Suction evacuation was very effective with a success rate of 202 of 221 (91.5%; 95% confidence interval, 87.8-95.2), whereas systemic methotrexate was least effective with only 38 of 64 (59.4%; 95% confidence interval, 48.4-70.4) patients not requiring additional treatment. Overall, surgical treatment of cesarean scar pregnancies was successful in 236 of 258 (91.5%, 95% confidence interval, 88.4-94.5) patients and complications were observed in 24 of 258 patients (9.3%; 95% confidence interval, 6.6-11.9). CONCLUSION: A cesarean scar pregnancy can be managed effectively in the first trimester of pregnancy in more than 90% of cases with either suction evacuation, balloon treatment, or surgical excision. The effectiveness of all treatment options decreases with advancing gestational age, and cesarean scar pregnancies should be treated as early as possible after confirmation of the diagnosis. Local medical treatment with potassium chloride or methotrexate is less efficient and has higher rates of complications than the other treatment options. Systemic methotrexate has a substantial risk of failing and a higher complication rate and should not be recommended as first-line treatment.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Kaelin Agten, Andrea;  Liverpool Women's Hospital NHS Foundation Trust, Liverpool, United Kingdom. Electronic address: a.kaelin@gmail.com
Jurkovic, Davor;  University College London, London, United Kingdom
Timor-Tritsch, Ilan;  Hackensack Meridian School of Medicine, Nutley, NJ
Jones, Nia;  University of Nottingham, Nottingham, United Kingdom
Johnson, Susanne;  Princess Anne Hospital, University Hospitals Southampton, Southampton, United Kingdom
Monteagudo, Ana;  Icahn School of Medicine Mount Sinai, New York, NY
Huirne, Judith;  Amsterdam University Medical Centers, Amsterdam, Netherlands
Fleisher, Jonah;  University of Illinois at Chicago, Chicago, IL
Maymon, Ron;  Department of Obstetrics and Gynecology, Shamir Medical Center (Assaf Harofeh), Be'er Ya'akov, Israel
Herrera, Tania;  Pacifica Salud Hospital, Panama City, Panama
Prefumo, Federico;  Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
Contag, Stephen;  Division of Maternal Fetal Medicine, University of Minnesota, Minneapolis, MN
Cordoba, Marcos;  Corewell Health West, Grand Rapids, MI
Manegold-Brauer, Gwendolin;  Division of Gynecologic and Prenatal Ultrasound, Department of Obstetrics and Gynecology, University of Basel, Basel, Switzerland. Electronic address: gwendolin.manegold-brauer@usb.ch
CSP Collaborative Network
More authors (5 more) Less
Other collaborator :
Chantraine, Frédéric  ;  Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique, partim Obstétrique
Language :
English
Title :
First-trimester cesarean scar pregnancy: a comparative analysis of treatment options from the international registry.
Publication date :
June 2024
Journal title :
American Journal of Obstetrics and Gynecology
ISSN :
0002-9378
eISSN :
1097-6868
Publisher :
Elsevier, United States
Volume :
230
Issue :
6
Pages :
669.e1 - 669.e19
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
The study was supported by unrestricted grants from the Bangerter-Rhyner Stiftung and the Freiwillige Akademische Gesellschaft Basel. The funding institutions did not have any role in conducting the study or manuscript preparation.The study was supported by unrestricted grants from the Bangerter-Rhyner Foundation and the Voluntary Academic Society Basel (FAG). The funding institutions did not have any role in conducting the study or manuscript preparation.
Available on ORBi :
since 02 July 2025

Statistics


Number of views
32 (0 by ULiège)
Number of downloads
18 (0 by ULiège)

Scopus citations®
 
24
Scopus citations®
without self-citations
20
OpenCitations
 
5
OpenAlex citations
 
28

Bibliography


Similar publications



Contact ORBi